Refine Search

New Search

Result: 1

(searched for: (title:(Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment)
Save to Scifeed
Page of 1
Articles per Page
by
Show export options
  Select all
Ashok Chakraborty, Anil Diwan
Journal of Biomedical Research & Environmental Sciences, Volume 1, pp 431-438; doi:10.37871/jbres1175

Abstract:
Potential clinical benefit in SARS-CoV-2 infection upon remdesivir treatment has been established. Recently, FDA has granted full approval for the clinical use of remdesivir for COVID therapy. However, the efficacy of remdesivir alone or in combination with other antivirals is still open to research, especially in terms of benefits vs. risk ratio. We here review remdesivir therapy based on a search for relevant pharmacological evidences with regards to the Pharmacokinetics (PK) and Pharmacodynamics (PD) of appropriate antiviral compounds against COVID-19 alone or in combination with other potential therapies. Drug–Drug Interactions (DDIs), if any in case of combo treatments have also been taken into consideration. We found promising in vitro evidence for efficacy of remdesivir, in combination with (hydroxy) chloroquine and/or favipiravir against SARS-CoV-2 infection in cell culture studies. However, clinical trial results from these combinations were not in line with the promising in vitro data, and therefore limit the use of such combinations in practice. Remdesivir and antibody therapies have also been used clinically either in combination or in sequential application. However, there are no substantive evaluable clinical data on these uses as of now. Additionally, some other drug combinations with remdesivir have been proposed in this article for future improvement in therapies.
Page of 1
Articles per Page
by
Show export options
  Select all
Back to Top Top